Ribon Therapeutics
35 Cambridgepark Drive
Cambridge
MA
02140
United States
Tel: 617-914-8700
Website: https://ribontx.com/
Email: info@ribontx.com
38 articles about Ribon Therapeutics
-
Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Severe Atopic Dermatitis
3/9/2023
Ribon Therapeutics today announced dosing the first patient in the open-label cohort of patients with moderate-to-severe atopic dermatitis to measure the pharmacodynamic activity of RBN-3143 and evaluate the safety and preliminary efficacy of 28 days of administration of RBN-3143 in this target population.
-
Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer
1/30/2023
Ribon Therapeutics, a clinical-stage biotechnology company developing therapeutics to target stress support pathways, today announced a $25 million investment from Pfizer.
-
Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim
11/29/2022
Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the acquisition of its CD38 program with Boehringer Ingelheim.
-
Ribon Therapeutics Announces Late-Breaking Presentation of Preclinical Data on RBN-3143 at the European Respiratory Society International Congress 2022
9/6/2022
Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced in a late-breaking presentation, compelling preclinical data for RBN-3143, a novel, orally administered, first-in-class inhibitor of PARP14 with potential in a range of inflammatory diseases.
-
Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting
4/11/2022
Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that an oral presentation and poster presentation for RBN-2397, the Company’s lead development candidate, was presented today, April 11, 2022, at the American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, Louisiana.
-
Ribon Therapeutics Announces Initiation of Phase 1b/2 Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung
3/29/2022
Ribon Therapeutics today announced the first patient has been dosed in the Phase 1b/2 study of RBN-2397 in combination with the anti-PD-1 checkpoint inhibitor therapy, pembrolizumab, in patients with squamous cell carcinoma of the lung (SCCL).
-
Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis
3/22/2022
Ribon Therapeutics today announced that it initiated the healthy volunteer portion of its Phase 1, first-in-human, single ascending dose and multiple ascending dose (SAD/MAD) safety and pharmacokinetic study of RBN-3143.
-
BioSpace Movers & Shakers, Feb. 25
2/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth
2/17/2022
Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that the Board of Directors has appointed Prakash Raman, Ph.D., as President, Chief Executive Officer and member of the Board of Directors.
-
Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech
9/27/2021
Ribon Therapeutics today announced it has been named by Fierce Biotech as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
-
Ribon Therapeutics Announces Key Management Promotions
9/1/2021
Ribon Therapeutics today announced the promotions of Heike Keilhack, Ph.D., to Chief Scientific Officer and Kevin Kuntz, Ph.D., to Chief Drug Development Officer.
-
Ribon Therapeutics Secures $65 Million Financing
7/14/2021
Ribon Therapeutics announced the closing of a $65 million financing.
-
In an interview with BioSpace, CEO Victoria Richon expressed her excitement about investor support and developing novel, first-in-class treatments.
-
Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer
6/28/2021
Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, announced the appointment of Paul Brannelly as Chief Financial Officer.
-
Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients with Advanced Solid Tumors at 2021 ASCO Annual Meeting
6/4/2021
- RBN-2397 was well tolerated and demonstrated evidence of target inhibition and preliminary signs of clinical activity - One partial response (PR) and nine patients with stable disease (SD) > 4 months in a heavily pretreated, heterogenous patient population
-
Ribon Therapeutics Announces Oral Presentation of RBN-2397 Clinical Data at 2021 ASCO Annual Meeting
5/20/2021
Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that data from its first-in-human Phase 1 trial evaluating RBN-2397, its small molecule inhibitor of PARP7, as a monotherapy in patients with advanced solid tumors was selected for an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Ribon Therapeutics Announces Upcoming Presentation on RBN-2397 at the 2021 ASCO Annual Meeting
4/29/2021
Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced an oral presentation on RBN-2397 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 4 to 8, 2021
-
Ribon Therapeutics Announces Upcoming Presentations at the AACR 2021 Virtual Annual Meeting
4/6/2021
Ribon Therapeutics, a clinical stage oncology company developing therapeutics targeting stress support pathways, today announced that it will present one oral and four poster presentations at the American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting (Week 1), taking place from April 10 to 15, 2021. Abstracts are available at: www.aacr.org .
-
Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases. Here’s a...
-
Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries
2/2/2021
Ribon Therapeutics, a clinical stage oncology company developing therapeutics targeting stress support pathways, today announced it has entered into an exclusive license agreement with Ono Pharmaceutical Co., Ltd., for the development and commercialization of RBN-239